Maternal Respiratory Syncytial Virus Prefusion F Vaccination and Acute Respiratory Illness in Infants - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Impact of Maternal Vaccination Against Respiratory Syncytial Virus Prefusion F on Acute Respiratory Illness in Infants

  • By

  • Anne-Marie Rick

  • Jennifer Deese

  • Jessica E. Kerr

  • Jonathan Hui

  • Hui Liu

  • Guan Yu

  • Chung-Chou H. Chang

  • Nicole Fazio

  • Muhammad H. Tahir

  • Rachael Bieltz

  • Anjani Ravindra

  • Christina Megli

  • Arun Jeyabalan

  • Sarah J. Pugh

  • Divya Patel

  • Rong Fan

  • Jessica E. Atwell

  • Alejandro Cané

  • Judith M. Martin

  • June 5, 2026

Share

Objective:

To evaluate the effectiveness of maternal RSVpreF vaccination against hospitalization for RSV-associated acute respiratory illness (ARI) and lower respiratory tract disease (LRTD) in infants.

Key Findings:
  • The pivotal phase 3 trial showed RSVpreF efficacy of 57.6% against RSV-associated medically attended LRTD and 82.4% against severe LRTD.
  • Vaccine effectiveness against RSV-associated hospitalization was 69.7% for infants aged 0 to 90 days.
  • The study found that maternal vaccination significantly reduced the incidence of RSV-associated ARI in infants, indicating a protective effect of the vaccine.
Interpretation:

The findings suggest that maternal RSVpreF vaccination may play a crucial role in reducing the risk of severe respiratory illness in infants. However, further studies are necessary to confirm these results and explore the long-term effects of vaccination.

Limitations:
  • The study relies on electronic health records, which may have limitations in data completeness and accuracy.
  • Exclusion criteria may limit generalizability to broader populations.
Conclusion:

Maternal vaccination with RSVpreF appears to be effective in reducing the risk of RSV-associated hospitalizations in infants, particularly in the early months of life. These findings underscore the importance of maternal immunization strategies in protecting vulnerable populations from respiratory illnesses.

Original Source(s)

Maternal Respiratory Syncytial Virus Prefusion F Vaccination and Acute Respiratory Illness in Infants

  • by Anne-Marie Rick, Jennifer Deese, Jessica E. Kerr, Jonathan Hui, Hui Liu, Guan Yu, Chung-Chou H. Chang, Nicole Fazio, Muhammad H. Tahir, Rachael Bieltz, Anjani Ravindra, Christina Megli, Arun Jeyabalan, Sarah J. Pugh, Divya Patel, Rong Fan, Jessica E. Atwell, Alejandro Cané, Judith M. Martin

  • June 5, 2026

Related Content

Global, regional, and national burden of pathogen-attributable infectious diseases in children by age and sex, 1990–2021: a systematic analysis

ACOG Releases 2026 Maternal Immunization Schedule

Thirteen other organizations endorsed guidance that extends across pregnancy, postpartum care, and lactation.

Correction: Clinical utility of a host-protein test for suspected infection in the pediatric emergency department: a pragmatic pre-/post-implementation study